Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

dacarbazine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor

Related drugs:

‹

captisol-enabled melphalan (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

carmustine (14)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

›

No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Uveal Melanoma	No biomarker	Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2	gemcitabine + dacarbazine Sensitive: A2 - Guideline gemcitabine + dacarbazine Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Neuroendocrine Tumor	No biomarker	Neuroendocrine Tumor	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive : A2	paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive: A2 - Guideline paclitaxel + albumin-bound paclitaxel + dacarbazine Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2	doxorubicin hydrochloride + dacarbazine Sensitive: A2 - Guideline doxorubicin hydrochloride + dacarbazine Sensitive : A2
BRAF V600E	Cutaneous Melanoma	BRAF V600E	Cutaneous Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3	cisplatin + dacarbazine Sensitive: C3 – Early Trials cisplatin + dacarbazine Sensitive : C3